Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hypnosis may ease chemo anxiety in teens and young adults

NCT ID NCT07614620

Symptom relief Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a single hypnosis session during chemotherapy can reduce anxiety and other side effects like nausea in young people with cancer. It includes 70 participants aged 15-49 with sarcoma, germ cell tumors, or breast cancer. Researchers will compare anxiety levels after chemo with and without hypnosis to see if it makes a difference.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hypnosis
What this could lead to
If it works, this could offer a low-cost, drug-free way to ease anxiety and nausea during chemotherapy for young cancer patients.
What could go wrong
This is a small, early-stage study with only 70 participants. Results may not apply to all patients, and hypnosis may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 49 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Newly diagnosed patients receiving initial care and follow-up at the Institut Bergonié during treatment: 1. Adolescents or young adults (AJA) aged 15 to 39 with soft tissue or bone sarcoma or a germ cell tumor (testicular, ovarian), 2. Young women aged 15 to 49 with breast cancer. 2. Treatment with neoadjuvant chemotherapy based on anthracyclines and/or alkylating agents. 3. Treatment administered as: 1. Inpatient for patients with soft tissue or bone sarcoma or a germ cell tumor (testicular, ovarian), 2. Outpatient or day hospital for female patients with breast cancer. 4. Dated and signed informed consent (if the patient is a minor, consent must also be signed by the legal guardians). 5. Patient enrolled in a social security program in accordance with current regulations. Exclusion Criteria: 1. Known contraindications to hypnosis (psychotic disorders, mental disorders, confusion, deafness, severe cognitive impairment, etc.) 2. Patients who have already undergone hypnosis sessions within 6 months prior to enrollment. 3. Geographic, social, or psychological factors rendering the patient unable to comply with the study's follow-up and procedures. 4. Patients who are deprived of their liberty or subject to a legal protection measure (guardianship, conservatorship, judicial protection, or family authorization).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm germ cell tumor ovarian cancer ovarian neoplasm sarcoma testicular germ cell tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Germ cell tumor of testis Ovarian tumor Sarcoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.